The European Medicines Agency has granted orphan drug status to LTI-03, an inhaled therapy being developed for people with ...

Artificial intelligence has come a long way, writes columnist Sam Kirton, who argues for its role in medicine and in his own care with PF.

Columnist Kylene Henderson is starting the year by focusing on progress and wellness, even if it means only small changes.

New Phase 2a data show the oral IPF therapy GRI-0621 modulates immune cell activity in adults with idiopathic pulmonary ...

Columnist Ann Reynoso may have looked well during a recent holiday gathering, but living with PF meant she was battling ...

Columnist Sam Kirton explores what options are available to help IPF patients meet the costs of their medical care and medications.

The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast), taken as oral tablets, as a treatment for adults with progressive pulmonary fibrosis (PPF), in which lung scarring ...

There are moments in life when love challenges us to rise in unexpected ways, testing our resilience and adaptability while revealing the quiet strengths we didn’t know we had. I am currently ...

Building on positive Phase 2 data, Puretech Health plans to launch a Phase 3 trial in the coming months to further test its experimental oral therapy deupirfenidone (LYT-100) in people with idiopathic ...

A novel inhalable therapy has shown promise for treating idiopathic pulmonary fibrosis (IPF) by outperforming an approved oral medicine in a mouse study. The new treatment, called VB-RT NPs, consists ...

The naturally occurring antioxidant alpha-lipoic acid, or ALA, which protects cells against the toxic effects of iron overload, may help reduce lung damage caused by silica — dust particles often ...